Boston Scientific
BSX
$46.92
+0.34%
Boston Scientific Corporation is a global leader in the development, manufacturing, and marketing of less-invasive medical devices used in a wide range of interventional medical specialties, including cardiology, neuromodulation, and endoscopy. As a major player in the Medical Devices industry, the company is distinguished by its broad and innovative portfolio aimed at improving patient outcomes with minimally invasive technologies. The current investor narrative is dominated by its strategic $1.5 billion investment to enter the high-growth transcatheter aortic valve replacement (TAVR) market, a move analysts view favorably, though this is juxtaposed against recent stock pressure following underwhelming clinical trial results and a broader market sell-off impacting large-cap healthcare names.…
BSX
Boston Scientific
$46.92
Related headlines
BSX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $61.00 and implied upside of +30.0% versus the current price.
Average Target
$61.00
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$38 - $61
Analyst target range
A cohort of 12 analysts provides coverage, and the institutional ratings show a unanimously bullish sentiment, with all recent actions from firms like Goldman Sachs, Citigroup, and Wells Fargo being Buys or Overweight, indicating strong professional conviction. The consensus average target price is implied through estimated metrics, with an average EPS estimate of $5.195 on average revenue of $30.5935 billion; applying the forward P/E of 12.59x to the EPS estimate suggests a consensus price target near $65.40, which would imply a substantial upside of approximately 39% from the current price of $46.91. The target range, derived from estimated EPS, spans from a low of $5.09 to a high of $5.41, translating to a price range of roughly $64.10 to $68.10 using the forward multiple; the high target likely assumes successful integration of recent acquisitions and market share gains, while the low target may factor in execution risks or competitive pressures. The tight clustering of EPS estimates and the unanimous Buy ratings signal high analyst conviction in the company's fundamental outlook and the potential for a recovery, despite the stock's recent technical breakdown.
BSX Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -52.40% and a 6-month decline of -49.33%. As of the latest close at $46.91, the price is trading near the bottom of its 52-week range, approximately 1.6% above the 52-week low of $45.99, indicating the stock is deeply oversold and potentially in a capitulation phase, though it remains a falling knife without clear signs of a bottom. Recent momentum is severely negative and accelerating the longer-term downtrend, with the stock down -11.59% over the past month and -32.14% over the past three months; this sharp short-term decline, coupled with a relative strength reading of -11.51 against the SPY over one month, highlights intense selling pressure and significant underperformance. Key technical support is firmly established at the 52-week low of $45.99, while resistance is far overhead at the 52-week high of $109.50; a breakdown below $45.99 could trigger another leg down, whereas any recovery would face immense overhead supply. The stock's beta of 0.56 indicates it has been significantly less volatile than the broader market during this sell-off, which is unusual for a growth-oriented med-tech name and may suggest the decline is driven by company-specific rather than systemic factors.
Beta
0.56
0.56x market volatility
Max Drawdown
-56.8%
Largest decline past year
52-Week Range
$46-$110
Price range past year
Annual Return
-53.8%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | -10.9% | +1.5% |
| 3m | -34.2% | +13.4% |
| 6m | -51.2% | +10.9% |
| 1y | -53.8% | +24.5% |
| ytd | -50.5% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $5.286 billion representing a 15.9% year-over-year increase, and segment data shows the Cardiovascular business ($3.493B) is the primary growth driver, significantly larger than MedSurg ($1.814B). The multi-quarter trend shows consistent top-line expansion, with revenue growing from $4.563 billion in Q4 2024 to the latest $5.286 billion, supporting a strong underlying commercial story. The company is solidly profitable, reporting Q4 2025 net income of $668 million and a gross margin of 74.48%, which reflects its premium product portfolio; profitability has improved markedly year-over-year, as net income grew from $566 million in Q4 2024, and the trailing twelve-month net margin stands at 14.38%. Operating margin for Q4 2025 was 22.81%, indicating effective cost control and scaling of the business model. Balance sheet health is reasonable, with a debt-to-equity ratio of 0.51 and a current ratio of 1.62, suggesting adequate liquidity and a manageable leverage profile. The company generates substantial cash, with free cash flow over the trailing twelve months at $3.625 billion, providing ample internal funding for growth initiatives like the recent $1.5 billion acquisition; return on equity of 11.91% demonstrates decent capital efficiency, though it has compressed from higher levels seen in prior quarters.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+0.15%
YoY Comparison
Gross Margin
+0.74%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Given the positive net income of $668 million in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 48.91x, while the forward P/E is substantially lower at 12.59x; this wide gap implies the market expects a significant earnings recovery or growth acceleration in the coming year, likely factoring in the contributions from recent strategic investments. Compared to sector averages, the trailing P/E of 48.91x is at a premium, though the forward multiple of 12.59x appears more reasonable; the price-to-sales ratio of 7.03 and EV/Sales of 3.88 also suggest the market is valuing the company's revenue stream, albeit at a discount to its own historical sales multiples during higher-growth phases. Historically, the stock's own trailing P/E has ranged dramatically, from lows near 36x in late 2021 to highs above 118x in late 2022; the current 48.91x sits above the mid-point of this range, but given the severe price decline, this elevated multiple reflects compressed earnings rather than optimistic pricing, signaling the market is pricing in a earnings trough or specific headwinds.
PE
48.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 37x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple
